GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (MEX:BIIB) » Definitions » Median PS Value

Biogen (MEX:BIIB) Median PS Value : MXN5,448.19 (As of Jul. 15, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Biogen Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Biogen's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was MXN1131.942. Biogen's 10-Year median PS Ratio is 4.8131. Therefore, the Median PS Value for today is MXN5,448.19.

As of today (2024-07-15), Biogen's share price is MXN4250.00. Biogen's Median PS Value is MXN5,448.19. Therefore, Biogen's Price to Median PS Value for today is 0.78.

The historical rank and industry rank for Biogen's Median PS Value or its related term are showing as below:

MEX:BIIB' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.54   Med: 0.84   Max: 1.58
Current: 0.78

During the past 13 years, the highest Price to Median PS Value of Biogen was 1.58. The lowest was 0.54. And the median was 0.84.

MEX:BIIB's Price-to-Median-PS-Value is ranked better than
53.59% of 502 companies
in the Drug Manufacturers industry
Industry Median: 0.805 vs MEX:BIIB: 0.78

Biogen Median PS Value Historical Data

The historical data trend for Biogen's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Median PS Value Chart

Biogen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Median PS Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8,004.41 9,065.70 7,908.47 6,935.04 5,317.01

Biogen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6,274.44 5,756.87 5,761.05 5,317.01 4,818.45

Competitive Comparison of Biogen's Median PS Value

For the Drug Manufacturers - General subindustry, Biogen's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biogen's Price-to-Median-PS-Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biogen's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Biogen's Price-to-Median-PS-Value falls into.



Biogen Median PS Value Calculation

Biogen's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=1131.942*4.8131
=5,448.19

10-Year Median PS Ratio is 4.8131.
Biogen's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN1131.942.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biogen  (MEX:BIIB) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Biogen's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=4250.00/5,448.19
=0.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biogen Median PS Value Related Terms

Thank you for viewing the detailed overview of Biogen's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (MEX:BIIB) Business Description

Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

Biogen (MEX:BIIB) Headlines

From GuruFocus

Q3 2023 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q2 2022 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Biogen Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-22-2024

Q2 2021 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q1 2023 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024